I'll research ALGN before writing the preview. Let me gather recent earnings materials, guidance, and news in parallel.Let me read the most recent earnings materials and gather more context.I have strong Q1 detail. Let me pull recent news and the stock price trend heading into the print.Let me check for any recent analyst/news items and consensus estimates.I have enough to write a well-grounded preview. Let me do one final search for recent price-target/setup context.# Align Technology (ALGN) — Q2 FY2026 Earnings Preview
Report date: After market close, Wednesday, July 29, 2026 (Q2'26 earnings call to follow) Recent price: ~$175.63 (7/28 close) | YTD: ~+13% | 52-wk range context: trading well below the ~$196–$197 highs hit in Feb/April 2026 Street consensus (Q2'26): Revenue ~$1.05B (≈+3.9% YoY); non-GAAP EPS ~$2.63–$2.64 Company guide (Q2'26): Revenue $1.04B–$1.06B (+3–5% YoY); non-GAAP operating margin ~21.5% (GAAP ~16.4%)
Align enters this print with momentum on the fundamentals but a stock that has cooled off. Q1'26 was a clean beat-and-reaffirm: revenue of $1.04B (+6.2% YoY) topped the ~$1.02B consensus, Clear Aligner volume hit a record 685.7K cases (+6.7% YoY), and non-GAAP EPS of $2.58 (+21% YoY) beat by roughly 14%. Non-GAAP operating margin expanded ~240bps YoY to 21.5%, reflecting the payoff from 2024–2025 restructuring.
Despite the strong Q1, the shares have drifted from their February/April highs and sit around $175, with sell-side price targets clustered near $206–$209 (consensus "Buy"/"Moderate Buy"). That gap frames the setup: the market wants proof that the growth re-acceleration is durable — particularly in North America — before re-rating the stock. The stock bounced ~5% into the print (from ~$168 on 7/24 to ~$176 on 7/28), so expectations are not depressed.
The core question for Q2: Can Align sustain broad-based international strength and hold margins while North America stays soft — and does management have enough confidence to raise the full-year outlook it deliberately kept "prudent" in April?
| Metric | Q2'26 Consensus / Guide | Q1'26 Actual | Q2'25 (approx comp) |
|---|---|---|---|
| Total revenue | $1.04B–$1.06B guide; ~$1.05B cons. | $1.04B | ~$1.01B |
| Clear Aligner volume | Up seq. & YoY | 685.7K (record) | — |
| Clear Aligner ASP | Flat seq. & YoY (~$1,250) | $1,250 | ~$1,250 |
| Non-GAAP EPS | ~$2.63–$2.64 | $2.58 | ~$2.35 |
| Non-GAAP op. margin | ~21.5% | 21.5% | ~19% |
Full-year 2026 framework (reaffirmed in April): revenue +3–4% YoY; Clear Aligner volume +mid-single digits; GAAP op. margin slightly below 18% (~+400bps YoY); non-GAAP op. margin ~23.7% (+100bps YoY); ~100bps FX tailwind; capex $125M–$150M. FY26 EPS consensus sits near ~$9.48.
Because management called its full-year guide intentionally conservative, a guidance raise (or lack thereof) will likely be the single biggest swing factor for the stock's reaction.
1. North America Clear Aligner inflection. This is the crux. In Q1, North America was only "stable" (a modest YoY decline) while EMEA, APAC and LATAM all grew double digits. Management flagged early "green shoots" (improvement in the U.S. and Canada) and pointed to macro/consumer discretionary softness rather than share loss as the culprit. Watch for: any sequential improvement, orthodontist vs. GP/retail channel divergence, and whether U.S. patient traffic/conversion is recovering. A return to U.S. growth would be the clearest bull catalyst.
2. International durability — especially China. Q1's double-digit China growth and record APAC quarter surprised positively. Management was careful not to call China "normal," so watch whether that strength holds. LATAM (aided by Invisalign Pay financing) and EMEA (Iberia, Italy, UK, Nordics, Turkey) have been reliable engines.
3. Middle East overhang. Align baked "prudence" into its Q2 guide for potential hits to patient traffic, consumer demand, and freight from Middle East conflict — even though direct exposure is "single digits" of revenue and Q1 impact was immaterial. The bigger risk is indirect: higher fuel/inflation pressuring discretionary spend. Look for updated commentary; if the feared impact didn't materialize, that's a source of upside/de-risking.
4. ASP and mix. ASP guided flat YoY at ~$1,250, with a full-year expectation of a 1–2% decline as country/product mix (lower-priced markets, cheaper scanner configs) offsets FX and price increases. Importantly, the shift toward "Zero AA / no additional aligner" and DSP touch-up products is margin-accretive despite lower headline price, because it cuts manufacturing and treatment-planning cost.
5. Zero AA / no-additional-aligner adoption. Management said meaningful upside is not baked into the guide — adoption is a gradual, doctor-by-doctor rollout starting with DSOs and expanding into retail. Any evidence this is scaling faster (driving incremental case volume) would be a positive surprise.
6. Systems & Services (iTero). Q1 was seasonally soft (-12% sequentially) but +0.9% YoY; Q2 is guided up sequentially. Watch iTero Lumina adoption, the >125K active scanner installed base, exocad (double-digit growth), and the mix shift to lower-priced/leased/PC-based units. Capital equipment demand is a useful read on dental-office confidence.
7. Margin trajectory & second-half ramp. Q2 non-GAAP margin is guided flat vs. Q1 at ~21.5%, which implies a meaningful step-up in 2H to hit the ~23.7% full-year target. Investors will probe the credibility of that back-half acceleration (volume leverage, cost actions, mix, FX).
Align completed its $200M buyback (1.4M shares at avg $143.85) between Aug 2025 and Jan 2026, and launched another ~$200M repurchase over six months beginning ~May 1, 2026 — with $800M still authorized under the $1B program. Note the constraint management flagged: only ~20% of its ~$1.06B cash is U.S.-based, which limits the pace of buybacks. Q1 free cash flow was ~$120M. Expect questions on whether Align will lean in harder given the stock is off its highs.
At ~$175, ALGN trades around ~18–19x the ~$9.48 FY26 EPS consensus — reasonable for a high-margin franchise but reflecting the market's skepticism about growth durability. Analysts remain constructive (targets ~$206–$209), implying meaningful upside if Align can pair its margin story with a top-line re-acceleration. Recent price-target moves have been positive (e.g., Evercore to ~$220, Leerink to ~$230 following Q1).
Align has a credible margin-expansion story and consistent international momentum, and it has a track record of beating (Q1 topped EPS by ~14%; multi-quarter beat history). The bar for a positive reaction, however, is less about the Q2 beat itself — which the guide and consensus already point to — and more about two things: (1) signs that North America is finally inflecting, and (2) whether management upgrades its deliberately conservative full-year outlook. Given the stock already rallied into the print, a simple in-line beat-and-reaffirm may not be enough; investors want evidence that 2026 is an acceleration story, not just a stabilization one.
Watch on the call: North America case growth cadence, China durability, Middle East impact vs. the prudent assumption, Zero-AA/DSP adoption, the 2H margin ramp, and — most of all — any change to full-year guidance.
Note: Consensus estimates and price targets are drawn from public analyst compilations (Zacks/Yahoo/MarketBeat) and may differ from the specific broker you follow. Figures should be reconciled against your own model and the latest sell-side notes before the print.